Arthritis as an adverse event of special interest post COVID-19 vaccine implementation

COVID-19 vaccines are currently in development or being rolled out as a public health response to manage the pandemic. While selected for mass immunization programs would have demonstrated safety and efficacy Phase 3 trials, vaccine monitoring including reporting of adverse events following (AEFI) investigation reported cases still required surveillance. Monitoring AEFI post vaccination is quite relevant clinicians.